Homing pathways of mesenchymal stromal cells (MSCs) and their role in clinical applications

International Reviews of Immunology

Volumn 29, Issue 5, 2010, Pages 514-529

  Deak, Erika ^a   Seifried, Erhard ^a   Henschler, Reinhard ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

clinical applications; homing; Mesenchymal stromal cells; regulatory pathways

Indexed keywords

ANTIINFLAMMATORY ACTIVITY; BONE MARROW; BONE REGENERATION; CELL HOMING; CELL MIGRATION; CELL STIMULATION; CELL THERAPY; CELLULAR DISTRIBUTION; HEMATOPOIETIC CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STROMA CELL; TISSUE REGENERATION;

ANIMALS; CELL MOVEMENT; GUIDED TISSUE REGENERATION; HUMANS; IMMUNOMODULATION; MESENCHYMAL STEM CELLS; RECEPTORS, LYMPHOCYTE HOMING; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; STROMAL CELLS;

EID: 77956697181     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2010.498931     Document Type: Review

References (77)

1. Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol 1976; 4: 267-274.
2. Horwitz EM, Le Blanc K, Dominici M, et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytother-apy 2005; 7: 393-395.
3. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317.
4. Karp JM, Leng Teo GS. Mesenchymal stem cell homing: The devil is in the details. Cell Stem Cell 2009; 4: 206-216.
5. Pittenger MF, Mackay AM, Beck SC, et al. (1999). Multilineage potential of adult mesenchymal stem cells. Science 1999; 284: 143-147.
6. Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: Revisiting history, concepts, and assays. Cell Stem Cell 2008; 2: 313-319.
7. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 2006; 119: 2204-2213.
8. da Silva Meirelles L, Caplan AI, Nardi NB. In search of the in vivo identity of mesenchymal stem cells. Stem Cells 2008; 26: 2287-2299.
9. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007; 110: 3499-3506.
10. Springer T. 1994. Traffic signals for lymphocyte recirculation and leucocyte emigration: The multistep paradigm. Cell 1994; 76: 301-314.
11. GaoJ, Dennis JE, Muzic RF, etal. The dynamicin vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tiss Organs 2001; 169: 12-20.
12. Devine SM, Cobbs C, Jennings M, et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003; 101: 2999-3001.
13. Bensidhoum M, Chapel A, Francois S, et al. Homing of in vitro expanded Stro-1-or Stro-1+ human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment. Blood 2004; 103: 3313-3319.
14. Lee RH, Pulin AA, Seo MJ, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009; 5: 54-63.
15. Anjos-Afonso F, Siapati EK, Bonnet D. In vivo contribution of murine mesenchymal stem cells into multiple cell-types under minimal damage conditions. J Cell Sci 2004; 117: 5655-5664. doi:10.1242/jcs.01488.
16. Deak E, Rüster B, Keller L, et al. (2010) Suspension medium influences interaction of mesenchymal stromal cells with endothelium and pulmonary toxicity after transplantation in mice. Cytotherapy 2010; 12: 260-264.
17. Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci \USA 2003; 100: 8407-8411.
18. Koç ON, Gerson SL, Cooper BW, et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000; 18: 307-316.
19. Macmillan ML, Blazar BR, DeFor TE, Wagner JE. Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote en-graftment in pediatric recipients of unrelated donor umbilical cord blood: Results of a phase I-II clinical trial. Bone Marrow Trans 2009; 43: 447-454.
20. Lazarus HM, Koc ON, Devine SM, et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hema-tologic malignancy patients. Biol Blood Marrow Trans 2005; 11: 389-398.
21. Le Blanc K, Samuelsson H, Gustafsson B, et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia. 2007; 21: 1733-1738.
22. Rombouts WJ, Ploemacher RE. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia 2003; 17: 160-170.
23. Ball LM, Bernardo ME, Roelofs H, et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007; 110: 2764-2767.
24. Kim DW, Chung YJ, Kim TG, et al. Cotransplantation of third-party mesenchymal stromal cells can alleviate single-donor predominance and increase engraftment from double cord transplantation. Blood 2004; 103: 1941-1948.
25. Maitra B, Szekely E, Gjini K, et al. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Trans 2004; 33: 597-604.
26. Sensebé L, Krampera M, Schrezenmeier H, et al. Mesenchymal stem cells for clinical application. Vox Sang 2010; 98: 93-107.
27. Cilloni D, Carlo-Stella C, Falzetti F, et al. Limited engraftment capacity of bone marrow-derived mesenchymal cells following T-cell-depleted hematopoietic stem cell transplantation. Blood 2000; 96: 3637-3643.
28. Goan SR, Junghahn I, Wissler M, et al. Donor stromal cells from human blood engraft in NOD/SCID mice. Blood 2000; 96: 3971-3978.
29. Erices AA, Allers CI, Conget PA, et al. Human cord blood-derived mesenchymal stem cells home and survive in the marrow of immunodeficient mice after systemic infusion. Cell Transplant 2003; 12: 555-561.
30. Wynn RF, Hart CA, Corradi-Perini C, et al. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 2004; 104: 2643-2645.
31. Sackstein R, Merzaban JS, Cain DW, et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 2008; 14: 181-187.
32. Méndez-FerrerS, Frenette PS. Galpha(s) uncouples hematopoietic stem cell homing and mobilization. Cell Stem Cell 2009; 4: 379-380.
33. Horwitz EM, Gordon PL, Koo WK, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis im-perfecta: Implications for cell therapy of bone. Proc Natl Acad Sci \USA 2002; 99: 8932-8937.
34. Le Blanc K, Götherström C, Ringdén O, et al. Fetal mesenchymal stem-cell engraft-ment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation 2005; 79: 1607-1614.
35. Pereira RF, O'Hara MD, Laptev AV, et al. Marrow stomal cells as a source of progenitor cells for nonhemtapoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta. Proc Natl Acad Sci \USA 1998; 95: 1142-1147.
36. Marino R, Martinez C, Boyd K, et al. Transplantable marrow osteoprogenitors engraft in discrete saturable sites in the marrow microenvironment. Exp Hematol 2008; 36: 360-368.
37. Noël D, Djouad F, Bouffi C, et al. Multipotent mesenchymal stromal cells and immune tolerance. Leuk Lymphoma 2007; 48: 1283-1289.
38. Sato K, Ozaki K, Oh I, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109: 228-234.
39. Casiraghi F, Azzollini N, Cassis P, et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells 1. J Immunol 2008; 181: 3933-3946.
40. Ruster B, Gottig S, Ludwig RJ, et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 2006; 108: 3938-3944.
41. Shi M, Li J, Liao L, et al. Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: Role in homing efficiency in NOD/SCID mice. Haematologica 2007; 92: 897-904.
42. Ren G, Zhang L, Zhao X, et al. Mesenchymal stem cell-mediated immunosuppres-sion occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-150.
43. Wu GD, Nolta JA, Jin YS, et al. Migration of mesenchymal stem cells to heart allografts during chronic rejection. Transplantation 2003; 75: 679-685.
44. Förster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: Balancing immunity and tolerance. Nat Rev Immunol. 2008; 5: 362-371.
45. Gonzalo-Daganzo R, Regidor C, Martín-Donaire T, et al. Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults. Cytotherapy 2009; 11: 278-288.
46. Tyndall A, Uccelli A. Multipotent mesenchymal stromal cells for autoimmune diseases: Teaching new dogs old tricks. Bone Marrow Trans 2009; 43: 821-828.
47. Zhang Q, Shi S, Liu Y, et al. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J Immunol 2009; 183: 7787-7798.
48. Rafei M, Campeau PM, Aguilar-Mahecha A, et al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner.J Immunol. 2009; 182: 5994-6002.
49. Németh K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009; 15: 42-49.
50. Romieu-Mourez R, François M, Boivin MN, et al. Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. J Immunol 2009; 182: 7963-7973.
51. Kraitchman DL, Tatsumi M, Gilson WD, et al. Dynamic imaging of allogeneic mes-enchymal stem cells trafficking to myocardial infarction. Circulation 2005; 112: 1451-1461.
52. Freyman T, Polin G, Osman H, et al. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J 2006; 27: 1114-1122.
53. Martens TP, See F, Schuster MD, et al. Mesenchymal lineage precursor cells induce vascular network formation in ischemic myocardium. Nat Clin Pract Cardiovasc Med 2006; 3: S18-S22.
54. Segers VFM, Van Riet I, Andries LJ, et al. Mesenchymal stem cell adhesion to cardiac microvascular endothelium: Activators and mechanisms. Am J Physiol Heart Circ Physiol 2006; 290: H1370-H1377.
55. Ip JE, Wu Y, Huang J, et al. Mesenchymal stem cells use integrin b1 not CXC chemokine receptor 4 for myocardial migration and engraftment. Mol Biol Cell 2007; 18: 2873-2882.
56. Schenk S, Mal N, Finan A, et al. Monocyte chemotactic protein-3 is a myocardial MSC homing factor. Stem Cells 2007; 25: 245-251.
57. Belema-Bedada F, Uchida S, Martire A, et al. Efficient homing of multipotent adult MSCs depends on FROUNT-mediated clustering of CCR2. Cell Stem Cell 2008; 2: 566-575.
58. Cheng Z, Ou L, Zhou X, et al. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 2008; 16: 571-579.
59. Haider HKH, Jiang S, Idris NM, Ashraf M. IGF-1-overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF-1alpha/CXCR4 signaling to promote myocardial repair. Circ Res 2008; 103: 1300-1308.
60. Wagner DD, Frenette PS. The vessel wall and its interactions. Blood 2008; 111: 5271-5281.
61. Satoh H, Kishi K, Tanaka T, et al. Transplanted mesenchymal stem cells are effective for skin regeneration in acute cutaneous wounds. Cell Trans 2004; 13: 405-412.
62. Falanga V, Iwamoto S, Chartier M, et al. Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. Tissue Eng 2007; 13: 1299-1312.
63. Sasaki M, Abe R, Fujita Y, et al. Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. J Immunol 2008; 180: 2581-2587.
64. Zhang J, Gong JF, Zhang W, et al. Effects of transplanted bone marrow mesenchy-mal stem cells on the irradiated intestine of mice. J Biomed Sci 2008; 15: 585-594.
65. Sordi V, Malosio ML, Marchesi F, et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 2005; 106: 419-427.
66. Fiorina P, Jurewicz M, Augello A, et al. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol 2009; 183: 993-1004.
67. Kunter U, Rong S, Djuric Z, et al. Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. J Am Soc Nephrol 2006; 17: 2202-2212.
68. Herrera MB, BussolatiB,BrunoS,et al. Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Intl 2007; 72: 430-441.
69. Morigi M, Rota C, Montemurro T, et al. Life-sparing effect of human cord-blood mesenchymal stem cells in experimental acute kidney injury. Stem Cells. Retrieved 4 Jan 2010.
70. Dwyer RM, Potter-Beirne SM, Harrington KA, et al. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res 2007; 13: 5020-5027.
71. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007; 449: 557-563.
72. Breitbach M, Bostani T, Roell W, et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 2007; 110: 1362-1369.
73. Hsiao JK, Tai MF, Chu HH, et al. Magnetic nanoparticle labeling of mesenchymal stem cells without transfection agent: Cellular behavior and capability of detection with clinical 1.5 T magnetic resonance at the single cell level. Magn Reson Med 2007; 58: 717-724.
74. Walczak P, Zhang J, Gilad AA. Dual-modality monitoring of targeted intraarte-rial delivery of mesenchymal stem cells after transient ischemia. Stroke 2008; 39: 1569-1574.
75. Annabi B, Lee Y-T, Turcotte S, et al. Hypoxia promotes murine bone-marrow-derived stromal cell migration and tube formation. Stem Cells 2003; 21: 337-347.
76. De Becker A, Van Hummelen P, Bakkus M, et al. Migration of culture-expanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3. Haemato-logica 2007; 92: 440-449.
77. Ries C, Egea V, Karow M, et al. MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: Differential regulation by inflammatory cytokines. Blood 2007; 109: 4055-4063.